. Additionally, HLA class I is downregulated in HRS cells in 65% of the cHL cases and HLA class II in 40%, possibly as a strategy to escape from an effective immune surveillance [2] . All together, these factors may suppress the development of an effective anti-tumor response and provide a microenvironment that is favorable for the HRS cells.
Recent studies have suggested that T cells restricted to non-classical MHC class I-like CD1
molecules may be involved in immune surveillance of hematological malignancies [3] [4] [5] [6] . CD1 molecules are non-classical MHC class I-like molecules that present lipid antigens to T cells, triggering a specific immune response. Of the five CD1 isoforms (CD1a, CD1b, CD1c, CD1d and CD1e) expressed in human tissue, only CD1c and CD1d are expressed in B cells [7] .
The T cell receptors (TCRs) of T cells that recognize CD1c are indistinguishable from those that recognize MHC class I or II complexes. Most CD1c-restricted T cells appear to be TH-1like cells that provide adaptive immunity to microbial-lipid antigens [8] . In contrast, CD1d presents lipid antigens to natural killer T (NKT) cells. The best characterized CD1d-restricted These cells are characterized by the expression of an invariant Vα24Jα18 chain paired to a semi-invariant Vβ11 chain [9] . Two distinct functional subsets of human iNKT cells are recognized in terms of cytokines production and cytotoxic activation. CD4-iNKT cells are more likely to be cytotoxic and produce TH-1 type cytokines, whereas CD4+ iNKT cells are more likely to produce both TH-1 and TH-2 type cytokines after stimulation [10] . Several studies have shown the importance of iNKT cells in B cell malignancies [4] [5] [6] . In chronic lymphocytic leukemia (CLL) CD1d+ tumor cells loaded with αGalCer can activate iNKT cells and in turn induce cell death of tumor cells [4] . Malignant multiple myeloma is characterized by a reversible functional defect in iNKT cells in comparison with nonprogressive myeloma and premalignant myeloma [5] . Furthermore, iNKT cells were shown to induce effective antilymphoma responses and were essential for the survival of mice in murine lymphoma models [6] . The role of iNKT cells in the immune surveillance in cHL is unknown. Here, we examined the expression of CD1c and CD1d in HRS cells and tumor infiltrating cells in 44 cHL cases, as well as in four cHL cell lines. Furthermore, we studied the presence of iNKT cells in cell suspensions of ten cHL cases.
CD1c was undetectable in cHL cell lines L428, KMH2, L1236 and U-HO1 (data not shown).
In tonsil tissue, CD1c stained positive in the mantle zone (MZ) and predominantly negative in the germinal centers (GC) of secondary lymphoid follicles ( Figure 1A ) consistent with the previously reported expression pattern [11] . HRS cells in cHL were consistently CD1c negative in all cases ( Figure 1B ), while 14 out of 39 non Hodgkin lymphomas (NHL) were positive (Table I) 
. The absence of CD1c expression in both GC B cells and HRS cells is
consistent with the current assumption that HRS cells are derived from GC B cells [12] . CD1c expression has been reported in some other B-cell NHL subtypes, including GC B cell derived follicular lymphoma [11] . In B-cell NHL an inverse correlation was noticed between CD1c and the proliferative activity assessed by expression of Ki-67 [11] . This is in line with the lack of CD1c staining in GC B cells that show a high proliferation index and high CD1c expression in the MZ B cells that are in a resting state. Ki-67 was shown to be highly [13] correlating with the lack of CD1c expression. CD1c expression was found in reactive cells in all cases with a percentage varying from a few to the vast majority, similar to the CD1c expression pattern observed in interfollicular regions of tonsil tissue.
In contrast, CD1d was detected in all four cHL cell lines, varying from weakly positive in U-HO1 to strongly positive in the other three cHL cell lines ( Figure 1C -F). By flowcytometry we validated that CD1d was present on the membrane in cHL cell lines (data not shown). In normal tonsil tissue CD1d staining was observed mainly in the MZ and showed no positive staining in the GC ( Figure 1G ) consistent with the reported results [14] . CD1d was detected in HRS cells in 21 out of 44 cHL cases (48%) ( Figure 1H , Table I, supplementary table I), showing both cytoplasmic and membranous staining. No correlation was found with EBV status and CD1d expression (Table I) [4] and multiple myeloma [5] . In these B cell malignancies, iNKT cells activated by α-GalCer loaded CD1d+ tumor cells resulted in the induction of apoptosis of the tumor cells in vitro [4, 5] .
Since half of the cHL cases were positive for CD1d in HRS cells, we further investigated the iNKT cell population in cell suspensions of cHL and reactive lymph node (RLN). The mean percentage of iNKT cells was 4% (range 0.8-8%) in cHL and 4% (range 0.4-7%) in RLN (Table I) . iNKT cells were present at similar percentage in either CD1d positive or CD1d negative cHL cases. Two distinct iNKT subsets have been distinguished as Th1 type (CD4 -iNKT) and Th2 type (CD4 + iNKT) in terms of cytokine production and cytotoxic activation [10] .
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